Organization Profile

You just read:

Oncothyreon Expands Phase 2 Trial of its PI-3 Kinase Inhibitor PX-866 in Patients with Prostate Cancer

News provided by

Oncothyreon Inc.

Sep 05, 2012, 08:00 ET